Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"The risk for developing MS in an unaffected fraternal twin is 2%, and the risk in an identical twin is 25-30%."
http://neurology.ucsf.edu/msc/faq.htm
Ok, thanks Peter I understand his point, which is in line with the notes on the CETP variants in #msg-75772890. I can go on about the issue but I think Urche is right - it is time to move on. I'm sure the time will come to reopen the issue, perhaps at some other tea party :)
I honestly don't know what Levin would do about TEVA's existing partnerships. There are a lot of rearranging going on and my best guess is that each program will be re evaluated according to data and Levin's vision. The new CSO is a personalized medicine guy, so anything in this direction should be a winner...
In the link I've posted a few days ago ( http://genome.wellcome.ac.uk/doc_WTD020780.html ), there's an explanation on SCA. It is known and discussed in papers such as those mentioned in #msg-76009125 that rare genetic variants are frequently geographically localized to pockets around the globe rather than being widespread. If such variant has an advantage like resistance to malaria, then its frequency is very high due to selection in certain regions.
Urche, when I wrote
I was thinking that IDIX has a strong case with INX-189 given the similarities to IDX-184 and the strength of patents like #7,157,441.
Note that both studies looked at rare variants with minor allele frequency under 0.5%.
Advisory panel rejects Xarelto for ACS by 6-4-1 vote
Above all, Dr. Hayden is a geneticist
Teva's new President of Global R&D and Chief Scientific Officer
http://www.tevapharm.com/About/CorporateOfficers/Pages/Dr.%20Michael%20Hayden.aspx
Nexavar in lung cancer and KRAS
DiaPep277 got Orphan Drug Product Designations from the FDA. As the molecule has been around forever I assume patents are very old, so at least they'll have 7 years exclusivity if approved.
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=337111
Vinny
If you wish to keep calling the Apo1-A1 Milano allele a rare SNP instead of mutation, go ahead. You might want to read this before final decision http://genome.wellcome.ac.uk/doc_wtd020776.html . Either way, I think it's best if we leave the issue cause I might insult you once again and I really want to avoid doing that.
Idit
Let's just call it a very rare allele if you like, although the genetic literature calls it a mutation
There are only several hundreds carriers of the Milano mutant allele. Do you think its frequency can be even near 1%? It's a rethorical question of course.
SNP vs mutation
You are wrong. Please read and learn:
http://genome.wellcome.ac.uk/doc_WTD020780.html
Data suggest that genetic modulation of HDL doesn't affect the risk of MI. Still, our understanding of the whole picture is not complete. Some genes are not yet known, some complex interactions not fully understood and there are also surprising/confusing findings such as that at the HNF4A locus, the HDL raising allele is very much associated with increased risk of MI (p=0·0009).
It could make a good question testing grad students in basic genetics course.
Not that I'm holding my breath for CETP inhibitors but the cited 4% reduction in MI risk was calculated from the association between MI and SNPs and observed in genetic variant (modelled allele) near the CETP gene. CETP inhibitors might have a stronger effect on LDL (and on MI risk) than the predicted genetic variant plus they also reduce triglycerides and perhaps have an effect on ApoA-I, lpLPA2 and such.
BMY's anti-PD-1 BMS-936558 ASCO abstracts can be found here
http://abstractsearch.asco.org/cgi-bin/ts.pl?index=442064&query=BMS-936558&opt=any&submit.x=16&submit.y=9
From your post
Data look nearly appropriate for accelerated approval but I think ONXX will have a tough panel for the reasons I've mentioned.
ONXX/carfilzomib in MM
There's still the risk of exposure to radiation with CT colonography which imo is a hurdle.
Andromeda/DiaPep277
The article's headline is misleading saying the drug can "cures diabetic". The company never claimed that cause they know the vax can at best slow down progression to some degree for some patients. I've posted the news on the first phase III trial, which were better than those reported in the link you've posted from phase II, here: #msg-69237685 and here is the real latest PR:
http://www.andromedabio.com/page.php?pageID=80
Indeed the malignancies risk a real concern as it shows time-dependency pattern, but similar to what you've posted in #msg-75312624 I think RA docs want different drugs in the arsenal and they are familiar with immunosupressants side effects/risks and of course they will not put most patients on this drug.